Results 51 to 60 of about 6,725 (159)

Real-world overall survival in second-line maintenance niraparib monotherapy versus active surveillance in patients with wild-type recurrent ovarian cancer

Therapeutic Advances in Medical Oncology
Background: The NOVA study (NCT01847274) compared niraparib with placebo as a maintenance treatment for patients with recurrent ovarian cancer (OC) but was not powered to detect an overall survival (OS) improvement.
Robert L. Coleman, Jessica A. Perhanidis, Linda Kalilani, Nicole M. Zimmerman, Amanda Golembesky, Kathleen N. Moore   +5 more
doaj   +1 more source

Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential against gemcitabine-resistant PDAC

Translational Oncology
While poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) have achieved specific clinical benefits in a subset of pancreatic ductal adenocarcinoma (PDAC) patients, the potential role of the PARPi niraparib in PDAC necessitates further ...
Zehui Yao, Huihui Zhang, Kewei Huang, Guizhong Huang, Pu Xi, Lingmin Jiang, Dailei Qin, Fan Chen, Shengping Li, Ran Wei   +9 more
doaj   +1 more source

Micro/Nanostructured Materials and Microfluidic Diagnostic Platforms Enable Multimodal Detection of Circulating Tumor Cells

Exploration, Volume 6, Issue 5, October 2026.
Engineered micro/nanomaterials enable high‐efficiency CTC capture, release, and multimodal molecular profiling. Integrated with AI‐driven analytics, these platforms decode tumor heterogeneity and metastatic dynamics, advancing real‐time monitoring and precision oncology through DNA, RNA, and protein cross‐scale data fusion.
Hao Li, Jiaojiao Sun, Kunguo Liu, Shijie Wang, Bowen Fu, Hong Zhu, Peng Cao, Xin Han   +7 more
wiley   +1 more source

Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review

Frontiers in Oncology
Ovarian cancer (OC) is a common gynecological malignancy, and poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy has significantly prolonged the survival of newly diagnosed or platinum-sensitive recurrent ovarian cancer patients, which ...
Jiajun Li, Jiaxi Yang, Ying Wang
doaj   +1 more source

A novel RP-HPLC stability-indicating method for simultaneous estimation of Niraparib and Abiraterone in synthetic mixtures and combined tablet formulations

Discover Applied Sciences
Niraparib and Abiraterone in a combined dosage form offer a fortunate regimen for treating cancers, mainly those resistant to conventional therapies cast in cancer treatment.
Krishnaphanisri Ponnekanti, Ramreddy Godela, Divya Reddy Solipeta, K. Sujatha, Durga Prasad Beda   +4 more
doaj   +1 more source

Comparison of Different Maintenance Treatment Options for Newly Diagnosed wt Advanced Ovarian Cancer: A Retrospective Cohort Analysis

Technology in Cancer Research & Treatment
Introduction Niraparib and bevacizumab are two principal maintenance therapies for newly diagnosed advanced ovarian cancer (AOC) patients with BRCA wild-type ( BRCA wt) status, regardless of homologous recombination deficiency (HRD). In China, however, a
Xi Chen MD, Chenyan Fang MD, Yanglong Guo MD, Yingli Zhang PhD   +3 more
doaj   +1 more source

Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer

Clinical and Translational Medicine, Volume 16, Issue 11, November 2026.
Jesenia M. Perez, Justin Hwang, Britt K. Erickson, Stefani N. Thomas   +3 more
wiley   +1 more source

Healthy Participant Versus Patient Selection for Clinical Pharmacology Studies in Small‐Molecule Oncology Drug Development

Clinical and Translational Science, Volume 19, Issue 11, November 2026.
Paridhi Gupta, Zheyi Hu, Li Zhu, Lora Hamuro   +3 more
wiley   +1 more source

Olaparib and niraparib as maintenance therapy in patients with newly diagnosed and platinum-sensitive recurrent ovarian cancer: A single-center study in China

Chinese Medical Journal
. Background:. Poly adenosine-diphosphate-ribose polymerase (PARP) inhibitors (PARPi) have been approved to act as first-line maintenance (FL-M) therapy and as platinum-sensitive recurrent maintenance (PSR-M) therapy for ovarian cancer in China for >5 ...
Dengfeng Wang, Xunwei Shi, Jiao Pei, Can Zhang, Liping Peng, Jie Zhang, Jing Zheng, Chunrong Peng, Xiaoqiao Huang, Xiaoshi Liu, Hong Liu, Guonan Zhang, Yanjie Yin   +12 more
doaj   +1 more source

Between research and introduction to clinical routine—Experience with niraparib from the compassionate use program in Germany (NOGGO Register Analysis)

Archives of Gynecology and Obstetrics
Purpose Ovarian cancer (OC) is frequently diagnosed at a late, advanced stage, resulting in poor survival outcomes. PARP inhibitors like niraparib have shown significant efficacy in high-grade OC, particularly in tumors with homologous recombination ...
Jacek P. Grabowski, Julia Welz, Sabine Heublein, Maja Krajewska, Jolijn D. Boer, Fabian Kraus, Tjadina Arndt, Nicolas Moosmann, Bernhard Heinrich, Tobias Engler, Saida Agabejli, Mustafa Celalettin Ugur, Ralf Witteler, Oliver Albrecht, Harald Müller-Huesmann, Gülten Oskay-Özcelik, Cristina Hettwer, Sabrina Kaiser, Elena Braicu, Jalid Sehouli   +19 more
doaj   +1 more source